Primary structure of a new cysteine proteinase inhibitor from pig leucocytes  by Ritonja, Anka et al.
Volume 255, number 2, 211-214 FEB 07589 September 1989 
Primary structure of a new cysteine proteinase inhibitor from pig 
leucocytes 
Anka Ritonja, Majda Kopitar, Roman Jerala and Vito Turk 
Department of Biochemistry, J. Stefan Institute, Jamova 39,610OO Ljubljana, Yugoslavia 
Received 27 July 1989 
The primary structure of a pig leucocyte cysteine proteinase inhibitor, also called cathelin, was determined. The sequence 
was obtained from analyses of peptides i olated from the chymotryptic, endoproteinase Lys-C and protease V8 digests, 
and by analysis of the peptides derived from the hydrolysis of the aspartyl-prolyl bond of the carboxymethylated inhibit- 
or. The inhibitor consists of 96 residues. The N-terminal residue of the inhibitor is pyrrolidonecarboxylic acid. The amino 
acid sequence. of cathelin suggests he appearance of a new family of cysteine proteinase inhibitors. 
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1. INTRODUCTION 
Protein inhibitors of cysteine proteinases are 
widely distributed in living organisms. Among 
them are cystatins, which form a superfamily of 
structurally homologous proteins. The cystatin 
superfamily can be grouped into three families: the 
stefins, the cystatins and the kininogens [l-4]. In 
addition to this, a sequence homology of human 
plasma histidine-rich glycoprotein (HRG) and 
human a-2 HS-glycoprotein (a-2 HSG) with 
members of cystatin superfamily was reported 
[5,6]. It was found that a-2 HSG and HRG are 
composed of two cystatin-like segments suggesting 
that both glycoproteins represent a new family 
within the cystatin superfamily. However, 
although structurally homologous to cystatins, 
both glycoproteins have no inhibitory activity 
against known cysteine proteinases. Statistical 
analysis of the similarities between the sequences of 
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The nucleotide sequence presented here has been submitted to 
the EMBL/GenBank database under accession umber YO7506 
all homologous proteins, based on the presence of 
different copies of cystatin-like segments and the 
presence or absence of disulphide bonds, enables 
us to assign all known members of the cystatin 
superfamily into four types or families [7]. 
Recently, we isolated a new cysteine proteinase 
inhibitor from pig leucocytes [S]. The protein has a 
p1 of 4.8 and molecular mass of about 11 kDa. It 
was found to be a potent, tight-binding inhibitor of 
cathepsin L and papain. No appreciable inhibition 
of other cysteine proteinases was observed. 
The purpose of this paper is to present the 
primary structure of pig leucocyte cysteine pro- 
teinase inhibitor and to compare this sequence with 
those of cystatins. We discuss the possibility that 
this new inhibitor introduces a new family of cys- 
teine proteinase inhibitors. The name cathelin for a 
new inhibitor of cathepsin L is proposed. 
2. EXPERIMENTAL 
The chemicals used for Edman degradation and amino acid 
analysis were of sequenal grade from Applied Biosystems. Iodo- 
[3H]acetic acid was from Amersham, endoproteinase Lys-C 
from Boehringer Mannheim and protease V8 (S. aureus) from 
Miles Scientific (UK). TLCK treated cu-chymotrypsin was 
prepared according to [9]. 
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Cleavage at the aspartyl-prolyl bond in the carboxy- 
methylated protein was performed by the procedure used by 
Fraser and co-workers [lo], somewhat modified. Hydrolysis 
was performed for 70 h at 38°C in 50% acetic acid at a protein 
concentration of 3 mg/ml. Unblocking of the blocked a-amino 
group of the N-terminal amino acid residue in Asp-Pro peptide 
DPl was performed by the modified procedure developed by 
Blomback and Doolittle [ll]. Peptide DPl (1 nmol) was dissolv- 
ed in 50 ~1 of 1 .O M NaOH and the solution was maintained 
12 hat room temperature and 5 hat 37’C. After this period, the 
reaction mixture was neutralized with trifluoroacetic acid and 
the peptide with the liberated a-amino group was separated 
from the unreacted peptide. 
For the determination of free -SH groups, native and active 
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Total: 96 residues, Mr: 10 834. 
Fig. 1. Amino acid sequence and composition of inhibitor, and strategy of the sequence determination. The amino acid sequence of S- 
[‘Hlcarboxymethylated protein was determined by automated Edman degradation of the four endoproteinase Lys-C-generated peptides 
(Kl-K4), the nine protease V&generated peptides (El-E9), the four a-chymotrypsin generated peptides (Chl-Ch4) and of two DP pep- 
tides (DPl and DP2) obtained after acid hydrolysis of the Asp-Pro peptide bond. The peptide DPl was sequenced after reactivation 
of the a-amino group of the N-terminal amino acid residue. Cysteine residues were identified by the radioactivity of the S-[“Hlcarboxy- 
methylated erivative. 
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inhibitor were alkylated with iodo-[‘HIacetic acid without prior 
reduction. The protein was reduced with 2-mercaptoethanol in 
6 M guanidine hydrochloride, and carboxymethylated with 
iodo-[3H]acetic acid. 
Peptides were purified by gel chromatography and HPLC on 
an Applied Biosystems RP-18 column eluted with aqueous 
acetonitrile-containing trifluoroacetic acid. Samples were se- 
quenced with an Applied Biosystems model 470 A gas-phase se- 
quenator [ 121. Phenylthiohydantoin derivatives were identified 
on line with the 120 A HPLC [13]. 
3. RESULTS AND DISCUSSION 
Native and also reduced and carboxymethylated 
inhibitor failed to yield the N-terminal sequence in- 
dicating that its a-amino group was blocked. 
Reduced and carboxymethylated protein was 
hydrolyzed by endoproteinase Lys-C. The se- 
quence of the Kl peptide showed the presence of an 
Asp-Pro bond (see fig. 1). The acid-labile character 
of this bond was used for hydrolysis of the protein 
chain to obtain the 39-residue long N-terminally 
blocked peptide DPl and 57-residue long C- 
terminal peptide DP2. The DP2 peptide contain&d 
7 Pro residues amongst the first 24 residues and 
consequently the automated sequence stopped. 
The additional sequenal data were obtained 
from the peptides after protease V8 hydrolysis. The 
overlaps of the peptides were provided by the set of 
a-chymotryptic peptides. Val is considered to be 
1 2 
the C-terminal residue of the inhibitor, based on 
the specificity of endoproteinase Lys-C and the 
proteinase V8. The protein contains four Cys 
residues, presumably forming two disulphide 
bonds because no free -SH group was found. To 
obtain the N-terminal sequence of the protein, the 
DPl peptide was used for basic hydrolysis. Reac- 
tivation of a-amino group occurred about 50%, 
and its N-terminal sequence yielded a Glu residue. 
It was thus confirmed that pyrrolidonecarboxylic 
acid is the N-terminal residue of the inhibitor. 
We compared the amino acid sequence of 
cathelin with all known proteins of the cystatin 
supetfamily. The closest however, is the identity 
with bovine kininogen segment 1 and bovine col- 
ostrum cystatin (fig.2). Percentages (in paren- 
theses) of identical residues when the sequences are 
aligned as in fig.2 are: bovine segments 1, 2 and 3 
(22, 16 and 14), bovine colostrum cystatin (21) and 
chicken cystatin (16). Based on this low number, 
we consider this protein inhibitor as a member of a 
new family of cysteine proteinase inhibitors [18]. 
The most highly conserved residue Gly 9 
(chicken cystatin numbering) found in all known 
sequences of inhibitory cystatins [ 1,4], recently 
identified as being important for the inhibitory ac- 
tivity of cystatins [191, is not present in cathelin. Its 
N-terminal part is 17 residues shorter than that of 
3 4 Fj F, 
aficde12345678901234~87890123458789~1234~8789~12a34~8789~ 
a. ----------------------ELRYREAVLRAVDRLNEQSSEANLYRLLEL~~PPKA~EPP~TPK 
b. -----------QES-SQEIDCNDQDVF 
c. 
d. --GEDFLPPMVCVGCPKPIPVDSPDL 
e. 
f. 
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123458789012345678a~9~123455789~123488789~1234~8~b~~~ 
a. PVSFTVP;ETVCPRPTRQP-PELCDFKE-------KQCVSTVTLNPSIH-SL~I-S~NEI~SV 
b. SLKYQI 
Fig.2. Amino acid sequence of the pig leucocyte inhibitor cathelin (a), aligned with those of bovine kininogen segments 1(b), 2 (c) and 
3 (d) [14], bovine colostrum cystatin (e) [15], and chicken cystatin (f) [16,17]. Residues are numbered according to chicken cystatin. 
Alignment was done as described in [18]. 
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chicken cystatin (see fig.2) and is thus missing the 
whole part containing the Gly 9 residue. The 
shorter N-terminal part could not be the product of 
a proteinase digest because its N-terminal residue is 
pyrrolidonecarboxylic acid. Another important 
fact is that the highly conserved sequence QXVXG 
(residues 53-57) (see fig.2 and [1,4]) is not present 
in leucocyte inhibitor with the exception of the 
Gly 57 residue. Both highly conserved regions im- 
portant for the proposed interaction of cystatin 
with cysteine proteinases of the papain family [ 191 
are not present in pig leucocyte inhibitor cathelin, 
indicating that the interaction should be different. 
Recently, by X-ray diffraction studies, the model 
for the interaction of chicken cystatin and papain 
was proposed [20]. The exact interaction of pig 
leucocyte cathelin with cysteine proteinases re- 
mains to be established by the same approach from 
enzyme inhibitor crystals. 
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